Clinical and neurobiological effects of NIRS-controlled transcranial magnetic stimulation(rTMS) in patients with panic disorder during cognitive behavioural therapy (CBT) treatment

Not Applicable

• Conditions: F41.0; F40.01; Panic disorder [episodic paroxysmal anxiety]

• Registration Number: DRKS00006345
• Lead Sponsor: niversitätsklinikum Münster

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2013-10-21
• Study Start: 2014-07-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 67

Inclusion Criteria

DSM-IV Diagnosis of Panic Disorder with or without Agoraphobia

Exclusion Criteria

Any severe somatic disorder · Brain organic disorder · Substance abuse disorder · Schizophrenia · Schizoaffective disorder · Bipolar disorder · Severe major depression · Severe Personality Disorders (e.g Borderline personality disorder) · Suicidality · Epilepsy · Cardiac Pacemaker · Any metal parts within the head · past or current benzodiazepine treatment within 3 half-lives before study begin · past or current treatment with anticonvulsiva during the last 3 months · pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
clinical symptom severity: measured by means of the German version of the Panic and Agoraphobia scale (PAS; Bandelow, 1997), the Hamilton Anxiety Rating Scale (HAM-A; Hamilton, 1996) and the Cardiac Anxiety Questionnaire (CAQ; Eifert et al., 2000; Hoyer et al., 2005) at the following dates:<br>- at the begining of rTMS (repetitive transcranial magnetic stimulation) treatment<br>- after the first week of rTMS treatment<br>- after the second week of rTMS treatment<br>- at the end of rTMS treatment<br>- after nine weeks, to say at the end of CBT (cognitive behavioural therapy)<br>- at the first follow-up date three months after the end of CBT<br>- at the second follow-up date six months after the end of CBT

Secondary Outcome Measures

Name	Time	Method
prefrontal brain activation: measured by means of near-infrared spectroscopy, at the latest 48 hours before the first rTMS treatment and at the earliest 12 hours afte the last rTMS treatment